ReviewDialogues in clinical neuroscience2014
Epigenetic mechanisms in schizophrenia.
Review in Dialogues in clinical neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 89 citations in OpenAlex.
- Alterations in GABAergic Interneurons, Neuroinflammation, and Epigenetics: Potential Targets for Therapeutic Strategies in Schizophrenia.Current neuropharmacology · 2026Article
- Analysis of Normalizers and Neurodevelopment-Related microRNAs in the Prefrontal Cortex and in the Sperm of SHR Rats.International journal of molecular sciences · 2025Article
- A Refined Approach to Isolate Interneurons for High-Validity Epigenetic Studies in Human Brain Tissue.Methods and protocols · 2025Article
- miRNA-Based Diagnosis of Schizophrenia Using Machine Learning.International journal of molecular sciences · 2025Article
- Neuroinflammation and Schizophrenia: New Therapeutic Strategies through Psychobiotics, Nanotechnology, and Artificial Intelligence (AI).Journal of personalized medicine · 2024Review
- Maternal immune activation and role of placenta in the prenatal programming of neurodevelopmental disorders.Neuronal signaling · 2023Review
- Soma-to-germline transformation in chromatin-linked neurodevelopmental disorders?The FEBS journal · 2022Review
- Cell type-specific mechanism of Setd1a heterozygosity in schizophrenia pathogenesis.Science advances · 2022Article
- Histone Modifications in Neurological Disorders.Advances in experimental medicine and biology · 2022Review
- Fibroblast Growth Factor 9 as a Potential Biomarker for Schizophrenia.Frontiers in psychiatry · 2022Article
- A novel mind-set in primate experimentation: Implications for primate welfare.Animal models and experimental medicine · 2021Review
- Functional Analysis ofGenetics research · 2021Article
- Article
- Genomic Chaos Begets Psychiatric Disorder.Complex psychiatry · 2020Review
- DNA Methylation Analysis of the NR3C1 Gene in Patients with Schizophrenia.Journal of molecular neuroscience : MN · 2020Article
- NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.Schizophrenia research · 2020Review
- Use of the epigenetic toolbox to contextualize common variants associated with schizophrenia risk .Dialogues in clinical neuroscience · 2019Article
- Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments.Molecular neurobiology · 2019Article
- Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways.Frontiers in psychiatry · 2019Article
- Resting-state network connectivity and metastability predict clinical symptoms in schizophrenia.Schizophrenia research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a major psychiatric disorder that lacks a unifying neuropathology, while currently available pharmacological treatments provide only limited benefits to many patients. This review will discuss how the field of neuroepigenetics could contribute to advancements of the existing knowledge on the neurobiology and treatment of psychosis. Genome-scale mapping of DMA methylation, histone modifications and variants, and chromosomal loopings for promoter-enhancer interactions and other epigenetic determinants of genome organization and function are likely to provide important clues about mechanisms contributing to dysregulated expression of synaptic and metabolic genes in schizophrenia brain, including the potential links to the underlying genetic risk architecture and environmental exposures. In addition, studies in animal models are providing a rapidly increasing list of chromatin-regulatory mechanisms with significant effects on cognition and complex behaviors, thereby pointing to the therapeutic potential of epigenetic drug targets in the nervous system.
Indexed as
Identifiers
25364289PMC4214181W2232633305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.